Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide
- 111 Downloads
Data are lacking regarding overdose of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF).
Material and methods
We present the first report of suicidal attempt with E/C/F/TAF in a Human Immunodeficiency Virus-infected subject.
A reversible acute renal failure with no proximal tubulopathy and neuropsychiatric issues are discussed. E/C/F/TAF withdrawal resulted in favourable renal and neuropsychiatric outcomes. The suicide attempt seemed unrelated to the integrase strand transfer inhibitor, being evenly explained within the context of stressful personal conflicts.
A suicidal attempt with an E/C/F/TAF overdose in an HIV-infected patient, resulted in a favourable outcome from a renal and neuropsychiatric standpoint.
KeywordsElvitegravir/cobicistat/emtricitabine/tenofovir alafenamide Overdose Suicide attempt
Compliance with ethical standards
Conflict of interest
Hortensia Álvarez has received support for attending meetings from Janssen-Cilag, Gilead Sciences, ViiV Healthcare, AbbVie, and Merck Sharp and Dohme. Ana Mariño has received support for attending meetings from Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag and ViiV Healthcare. Josep M. Llibre has received grants from ViiV Healthcare and has received honoraria and consulting fees from Gilead Sciences, Merck Sharp and Dohme, Bristol-Myers Squibb, and ViiV Healthcare, all them outside the submitted work. The remaining authors declare no relevant conflicts of interest to the content of the manuscript.
Human rights statement
This is a research involving a human participant. The patient provided written consent for publication of his clinical record.
- 1.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed June 7, 2018
- 2.European AIDS Clinical Society. European guidelines for clinical management and treatment of HIV-1-infected adults in Europe, version 9.0. Available at http://www.eacsociety.org/files/guidelines_9.0-english.pdf. Accessed August 17, 2018.
- 4.Llibre JM, Esteve A, Miro JM, Mateo G, Curran A, Podzamczer D, Riera M. Discontinuation of DTG, EVG/c and RAL due to toxicity in a prospective cohort. In: Presented at 24rd annual conference on retroviruses and opportunistic infections (CROI); February 13–16 2017, Seattle, Washington, USA. Abstract P651.Google Scholar
- 8.Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicenter, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16:43–52.CrossRefGoogle Scholar
- 9.Post FA, Tebas P, Clarke A, Cotte L, Short WR, Abram ME, et al. Brief report: switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr. 2017;74:180–4.CrossRefGoogle Scholar
- 10.Gupta SK, Post FA, Arribas JR, Pozniak A, Podzamczer D, Clarke A, et al. Renal safety of TAF vs TDF or ABC in a pooled analysis of 27 phase 2/3 clinical trials. In: Presented at: 22nd international AIDS conference; July 23–27 2018, Amsterdam, The Netherlands. Abstract TUPEB113.Google Scholar
- 11.Arribas JR, Thompson M, Sax PE, Haas B, McDonald C, Wohl DA, et al. Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results. J Acquir Immune Defic Syndr. 2017;75:211–8.CrossRefGoogle Scholar
- 12.Gaur AH, Kizito H, Prasitsueubsai W, Rakhmanina N, Rassool M, Chakraborty R, et al. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Lancet HIV. 2016;3:e561–8.CrossRefGoogle Scholar
- 13.Huhn GD, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, et al. A randomized, open-label trial to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus darunavir in treatment-experienced HIV-1-infected adults. J Acquir Immune Defic Syndr. 2017;74:193–200.CrossRefGoogle Scholar
- 14.Gallant J, Brunetta J, Crofoot G, Benson P, Mills A, Brinson C, et al. Brief report: efficacy and safety of switching to a single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-1/hepatitis B-coinfected adults. J Acquir Immune Defic Syndr. 2016;73:294–8.CrossRefGoogle Scholar
- 15.Hodder S, Squires K, Kityo C, Hagins D, Avihingsanon A, Plotnikova Y, et al. Efficacy and safety of switching to E/C/F/TAF in virologically suppressed women. In: Presented at: 24rd annual conference on retroviruses and opportunistic infections (CROI); February 13–16 2017, Seattle, Washington, USA. Abstract P443.Google Scholar
- 16.GENVOYA Elvitegravir. cobicistat, emtricitabine, and tenofovir alafenamide. Tablet. Food and Drug Administration. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207561s002lbl.pdf. Accessed on May 13, 2018.
- 17.Eron JJ, Lelievre J-D, Kalayjian R, Slim J, Wurapa AK, Stephens JL, et al. Safety and efficacy of E/C/F/TAF in HIV-infected adults on chronic hemodialysis. In: Presented at: 25th annual conference on retroviruses and opportunistic infections (CROI; March 4–7 2018, Boston, MA. Abstract P732.Google Scholar
- 18.ISENTRESS Raltegravir. Film-coated tablets. Food and Drug Administration. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022145s038,205786s007,0203045s015lbl.pdf. Accessed on May 13, 2018.
- 19.TIVICAY Dolutegravir. Tablet Food and Drug Administration. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204790s007lbl.pdf. Accessed on May 13, 2018.
- 20.BIKTARVY Bictegravir emtricitabine, and tenofovir alafenamide. Tablet Food and Drug Administration. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf. Accessed on July 3, 2018.
- 22.Wohl DA, Cohen C, Gallant JE, Mills A, Sax PE, Dejesus E, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65:e118–20.CrossRefGoogle Scholar
- 23.Pozniak A, Flamm J, Antinori A, Bloch M, Ward D, Berenguer J, et al. Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. HIV Clin Trials. 2017;18:141–8.CrossRefGoogle Scholar
- 24.Arribas JR, DeJesus E, van Lunzen J, Zurawski C, Doroana M, Towner W, et al. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. HIV Clin Trials. 2017;18:118–25.CrossRefGoogle Scholar
- 25.Viswanathan P, Baro E, Soon G, Sherwat A, Struble K. Neuropsychiatric adverse events associated with integrase strand transfer inhibitors. In: Presented at: 24rd annual conference on retroviruses and opportunistic infections (CROI); February 13–16 2017, Seattle, Washington, USA. Abstract P372.Google Scholar
- 27.Beck AT, Schuyler D, Herman I. Development of suicidal intent scales. In: Beck AT, Resnick HLP, Lettieri DJ, editors. The prediction of suicide. Bowie: Charles Press; 1974. p. 45–56.Google Scholar